328 related articles for article (PubMed ID: 10833901)
1. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
2. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.
Petrescu A; Mârzan L; Codreanu O; Niculescu L
Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522
[TBL] [Abstract][Full Text] [Related]
5. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
6. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
7. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
8. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma.
Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J
Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of cell-cycle associated markers on paraffin embedded and formalin fixed needle biopsies of prostate cancer: correlation of p120 protein expression with AgNOR, PCNA/cyclin, Ki-67/MIB1 proliferation-scores and Gleason gradings.
Botticelli AR; Casali AM; Botticelli L; Zaffe D
Eur J Histochem; 1998; 42(1):41-8. PubMed ID: 9615190
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
12. [P53 expression and its clinical significance in prostatic carcinoma].
Jiang T; Jiang H; Song XS; Li XC; Li QL
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues.
Petraki CD; Gregorakis AK; Papanastasiou PA; Karavana VN; Luo LY; Diamandis EP
Prostate Cancer Prostatic Dis; 2003; 6(3):223-7. PubMed ID: 12970725
[TBL] [Abstract][Full Text] [Related]
14. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
15. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma.
Altinok G; Powell IJ; Che M; Hormont K; Sarkar FH; Sakr WA; Grignon D; Liao DJ
Prostate Cancer Prostatic Dis; 2006; 9(1):77-82. PubMed ID: 16331298
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix.
Cina SJ; Richardson MS; Austin RM; Kurman RJ
Mod Pathol; 1997 Mar; 10(3):176-80. PubMed ID: 9071723
[TBL] [Abstract][Full Text] [Related]
17. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.
Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO
Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227
[TBL] [Abstract][Full Text] [Related]
18. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
Shibata MA; Ward JM; Devor DE; Liu ML; Green JE
Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
20. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI
J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]